LEMAITRE VASCULAR INC·4

May 11, 5:08 PM ET

Jasinski Lawrence J 4

4 · LEMAITRE VASCULAR INC · Filed May 11, 2026

Research Summary

AI-generated summary of this filing

Updated

Lemaitre Vascular (LMAT) Director Jasinski Exercises Options, Sells Shares

What Happened

  • Lawrence J. Jasinski, a director of Lemaitre Vascular, exercised stock options on May 7, 2026 and sold shares the same day. He exercised/options conversions for 1,069 shares at $47.19 ($50,446), 924 shares at $54.65 ($50,497), and 865 shares at $101.12 ($87,469) — a total of 2,858 shares acquired through option exercise with an aggregate reported exercise cost of $188,412. On the same date he disposed of 3,943 shares in an open-market sale at $110.00 for proceeds of $433,730.

Key Details

  • Transaction date: May 7, 2026; Form filed May 11, 2026 (not marked late).
  • Exercises (M): 1,069 sh @ $47.19 ($50,446); 924 sh @ $54.65 ($50,497); 865 sh @ $101.12 ($87,469).
  • Sale (S): 3,943 sh @ $110.00 = $433,730 (open market).
  • Additional derivative entries listed as $0 disposals correspond to the conversion/settlement of the exercised options (see footnotes).
  • Shares owned following the transactions: not disclosed in the provided excerpt of the filing.
  • Footnotes from the filing:
    • F1: Shares were acquired upon exercise of options (reported in Table II).
    • F2: One option was fully vested and exercisable.
    • F3: Another option vests over three years (33.3% after one year, then equal annual installments).

Context

  • The same-day pattern of exercising options and selling shares often reflects a cashless exercise or a decision to monetize shares; here Jasinski both acquired 2,858 shares via exercise and sold 3,943 shares on the same day. The filing shows conversion entries for the exercised options (listed with $0 disposition value) plus an open-market sale for $433,730. This report is factual transaction reporting and does not state the insider's motivation.

Insider Transaction Report

Form 4
Period: 2026-05-07
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-05-07$47.19/sh+1,069$50,4466,868 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-05-07$54.65/sh+924$50,4977,792 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-05-07$101.12/sh+865$87,4698,657 total
  • Sale

    Common Stock

    2026-05-07$110.00/sh3,943$433,7304,714 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F2]
    2026-05-071,0692,140 total
    Exercise: $47.19From: 2022-12-12Exp: 2027-12-12Common Stock (1,069 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F3]
    2026-05-079241,848 total
    Exercise: $54.65From: 2023-12-08Exp: 2028-12-08Common Stock (924 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F3]
    2026-05-078651,729 total
    Exercise: $101.12From: 2024-12-06Exp: 2029-12-06Common Stock (865 underlying)
Footnotes (3)
  • [F1]Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
  • [F2]This option is fully vested and exercisable.
  • [F3]This option is exercisable and vests over a three-year period at a rate of 33.3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years.
Signature
/s/ Laurie A. Churchill, Attorney-in-fact|2026-05-11

Documents

1 file
  • 4
    ownership.xmlPrimary

    4